Lazard’s Healthcare Group completed its second in-depth study of global healthcare industry leaders, surveying more than 380 C-level executives and 70 investors across three sectors: Pharmaceuticals and Biotech; MedTech; and Healthcare Services. The executive respondents represented many of the largest healthcare companies globally.
The results of the 2019 Global Healthcare Leaders Study echo the concerns that healthcare executives expressed in 2017 on the need to address rising cost trends with value-based pricing models and scientific innovation. This year’s results, however, showed an increased focus on the potential impact of technological advances in artificial intelligence, machine learning and data analytics.
The central findings of the study include:
Pricing and reimbursement pressure continue to be among the top strategic challenges facing the industry
Transformation over the next 5-10 years is expected to come from different sources across healthcare sectors
Data analytics, artificial intelligence and machine learning are expected to have a transformative impact on the industry over the next five years
Pricing/reimbursement pressure and the need for innovation continue to drive strategic activity among healthcare companies